Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | POLD1 | P28340 | 1/20 | 0.56 |
| ▸ | TK1 | P04183 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011028 | 0.91 | TK1 (0.53) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL10684890 | 0.83 | POLB (0.54) | POLBPOLA1POLD1TK1 | |
| SCHEMBL6910401 | 0.83 | POLB (0.54) | POLBPOLA1POLD1TK1 | |
| SCHEMBL9814884 | 0.82 | TK1 (0.42) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL9814768 | 0.82 | TK1 (0.42) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL4596737 | 0.81 | TK1 (0.55) | POLBTK1LMNATSHRALB | |
| SCHEMBL9814738 | 0.81 | TK1 (0.41) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL9814855 | 0.80 | TK1 (0.41) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL9814737 | 0.80 | TK1 (0.41) | POLBPOLA1POLD1TK1LMNA | |
| SCHEMBL9814872 | 0.80 | TK1 (0.41) | POLBPOLA1POLD1TK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892509-B1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20220249539-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2022-08-11 | — | — | US | disclosed |
| US-11304964-B2 | Bolaamphiphilic compounds, compositions and uses thereof | LAUREN SCIENCES LLC (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2022-03-10 | — | — | US | disclosed |
| EP-2892511-B1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10378006-B2 | Near-infrared ray exposure system for biological studies | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180305679-A1 | NEAR-INFRARED RAY EXPOSURE SYSTEM FOR BIOLOGICAL STUDIES | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-10-25 | — | — | US | disclosed |
| EP-3283060-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20180021368-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2018-01-25 | — | — | US | disclosed |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016168580-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160279069-A1 | MATERIALS AND METHODS FOR SUSTAINED RELEASE OF ACTIVE COMPOUNDS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150306236-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2892510-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20150110875-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150104502-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2015-04-16 | — | — | US | disclosed |
| WO-2014039501-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20110213193-A1 | Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2011-09-01 | — | — | US | disclosed |
| EP-0286418-B1 | ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEMS FOR THE SAME | US COMMERCE (US) | 1992-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104502-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LGALS1, BOLA2; BOLA2B, LGALS2 | POLB 4471/4885POLA1 3710/4885POLD1 4792/4885 |
| US-20180021368-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | BOLA2; BOLA2B, LGALS1, LGALS2 | POLB 4657/4885POLA1 4048/4885POLD1 4844/4885 |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | POLB 4699/4885POLA1 4389/4885POLD1 4865/4885 |
| US-11304964-B2 | Bolaamphiphilic compounds, compositions and uses thereof | LGALS1, BOLA2; BOLA2B, LGALS2 | POLB 4471/4885POLA1 3710/4885POLD1 4792/4885 |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | POLB 4709/4885POLA1 4376/4885POLD1 4864/4885 |
| US-20160367678-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | POLB 4741/4885POLA1 4483/4885POLD1 4868/4885 |
| US-20150306236-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | BOLA2; BOLA2B, LGALS1, LGALS2 | POLB 4657/4885POLA1 4048/4885POLD1 4844/4885 |
| US-20150110875-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | POLB 4709/4885POLA1 4376/4885POLD1 4864/4885 |
| US-20220249539-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | BOLA2; BOLA2B, LGALS1, LGALS2 | POLB 4657/4885POLA1 4048/4885POLD1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.